07:00 , Jul 28, 2014 |  BC Week In Review  |  Company News

Endo, Medigene sales and marketing update

Endo’s Paladin Labs Inc. subsidiary launched Veregen sinecatechins in Canada to treat genital warts. The wholesale acquisition cost for a 15 g tube of Veregen is C$60.23 ($56.08). Veregen is applied as a...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Paladin, Triton Pharma deal

Paladin acquired fellow specialty pharma Triton for an undisclosed amount. Paladin said it expects Triton to contribute sales of about C$4 million ($3.7 million) in 2014 from its portfolio of dermatology, women's health and urology...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Clinical News

Veregen sinecatechins regulatory update

Medigene said Canada approved Veregen sinecatechins to treat genital warts. Medigene said Canadian partner Triton is expected to launch the product in the country next half. The topical formulation of polyphenols extracted from green tea...
07:00 , Apr 25, 2011 |  BC Week In Review  |  Company News

Epitome, Medigene, Mitsui, Triton Pharma Inc. deal

MediGene granted Triton exclusive, Canadian rights to develop and commercialize Veregen sinecatechins ointment to treat genital warts. Triton will be responsible for Canadian approval of the topical formulation of polyphenols extracted from green tea...